MAN TAI LAM MD
Prescription History 1790784692
Internal Medicine - Infectious Disease in El Paso, TX

NPI Status: Active since July 21, 2005

Contact Information

1221 N COTTON ST
EL PASO, TX
ZIP 79902
Phone: (915) 598-1600
Fax: (915) 351-6040

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MAN TAI LAM MD, an active Infectious Disease specialist practicing in El Paso, TX. Our medical registry currently tracks 17 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 537 documented patient claims. Among these therapy options, the most frequently utilized medication is Dovato, which accounts for 92 claims alone.


Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 78
30-Day Fills 78.0
Days Supply 2,340
TX State Average Benchmarks
Peer Average Claims83.0
Peer Average 30-Day Fills84.8
Peer Average Days Supply2,544
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $319,657.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,098.17

State Avg Cost Per Claim

$3,889.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cephalexin

Generic Formulation: CephalexinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 418
TX State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply368
Conservative Utilization

This provider writes prescriptions for this formulation 27.6% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $571.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.20

State Avg Cost Per Claim

$9.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Descovy

Generic Formulation: Emtricitabine/Tenofov AlafenamSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 1,080
TX State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills45.3
Peer Average Days Supply1,358
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $79,468.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,207.45

State Avg Cost Per Claim

$2,201.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dovato

Generic Formulation: Dolutegravir Sodium/LamivudineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 92
30-Day Fills 94.0
Days Supply 2,820
TX State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills42.8
Peer Average Days Supply1,279
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 119.0% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $285,522.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,103.50

State Avg Cost Per Claim

$2,868.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 2 drugs: dolutegravir and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Edurant

Generic Formulation: Rilpivirine HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
TX State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.9
Peer Average Days Supply566
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,887.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,452.89

State Avg Cost Per Claim

$1,412.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone.

Therapeutic Applications

Rilpivirine is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This medication is usually prescribed to people who have not taken any HIV medications before. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It blocks the virus from growing and infecting more cells. Rilpivirine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Isentress

Generic Formulation: Raltegravir PotassiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 1,220
TX State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply774
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 64.0% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $83,910.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,046.60

State Avg Cost Per Claim

$1,973.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.

Therapeutic Applications

Raltegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Raltegravir is known as an integrase inhibitor. It blocks the virus from growing and infecting more cells. Raltegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Isentress Hd

Generic Formulation: Raltegravir PotassiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 47
30-Day Fills 47.0
Days Supply 1,410
TX State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.9
Peer Average Days Supply616
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 135.0% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $92,768.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,973.80

State Avg Cost Per Claim

$1,983.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.

Therapeutic Applications

Raltegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Raltegravir is known as an integrase inhibitor. It blocks the virus from growing and infecting more cells. Raltegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Lamivudine

Generic Formulation: LamivudineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
TX State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply878
Conservative Utilization

This provider writes prescriptions for this formulation 40.9% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $715.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$55.04

State Avg Cost Per Claim

$151.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors-NRTI. Lamivudine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Lamivudine Hbv

Generic Formulation: LamivudineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.0
Days Supply 420
TX State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills18.2
Peer Average Days Supply539
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,388.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$115.73

State Avg Cost Per Claim

$197.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors-NRTI. Lamivudine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Nitrofurantoin

Generic Formulation: Nitrofurantoin MacrocrystalSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 230
TX State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills38.5
Peer Average Days Supply938
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $216.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.48

State Avg Cost Per Claim

$44.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.

Therapeutic Applications

Nitrofurantoin is an antibiotic used to treat or prevent certain bladder infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Pifeltro

Generic Formulation: DoravirineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
TX State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply793
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,686.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,792.92

State Avg Cost Per Claim

$1,737.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Doravirine belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Doravirine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Prezcobix

Generic Formulation: Darunavir/CobicistatSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
TX State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills43.6
Peer Average Days Supply1,301
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.3% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38,425.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,561.72

State Avg Cost Per Claim

$2,437.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: darunavir and cobicistat. Darunavir belongs to a class of drugs known as protease inhibitors. Cobicistat is used to increase (boost) the levels of darunavir. Darunavir/cobicistat is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Rukobia

Generic Formulation: Fostemsavir TromethamineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 960
TX State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.7
Peer Average Days Supply589
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 68.4% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $292,829.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,150.92

State Avg Cost Per Claim

$8,723.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Fostemsavir is changed in your body to its active drug form. It works by helping to prevent attachment of and entry of the (HIV-1) virus into healthy cells in your body. Fostemsavir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 14.7
Days Supply 368
TX State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.4
Peer Average Days Supply411
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $101.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.20

State Avg Cost Per Claim

$6.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Symtuza

Generic Formulation: Darunavir/Cob/Emtri/Tenof AlafSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 44
30-Day Fills 44.0
Days Supply 1,320
TX State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills48.4
Peer Average Days Supply1,451
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $215,775.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,903.98

State Avg Cost Per Claim

$4,640.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: darunavir, cobicistat, emtricitabine, and tenofovir alafenamide. Darunavir is known as a protease inhibitor. Cobicistat helps darunavir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor; both kinds of drugs are often called NRTIs. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Tivicay

Generic Formulation: Dolutegravir SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 1,170
TX State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills50.8
Peer Average Days Supply1,511
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $89,665.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,299.11

State Avg Cost Per Claim

$2,350.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Trogarzo

Generic Formulation: Ibalizumab-UiykSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
TX State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply345
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $146,520.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,270.77

State Avg Cost Per Claim

$7,680.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Ibalizumab belongs to a class of drugs known as monoclonal antibodies. Ibalizumab is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MAN TAI LAM MD provides transparency into local medical care patterns within El Paso, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.